SCHEMBL24434682

SCHEMBL24434682

CCc1csc(NC(=O)c2cccn2Cc2ccncc2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.46
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
POLB P06746 2/20 0.46
HPGD P15428 2/20 0.46
PKM P14618 1/20 0.46
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
KCNH2 Q12809 1/20 0.44
CNR2 P34972 3/20 0.43
CNR1 P21554 1/20 0.43
SCN3A Q9NY46 5/20 0.43
HTT P42858 3/20 0.43
KMT2A Q03164 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
KDM4E B2RXH2 2/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24435120 0.89 AOC3 (0.45) SMN1; SMN2NPC1RAB9APOLBHPGD
SCHEMBL24434913 0.89 SMN1; SMN2 (0.43) SMN1; SMN2NPC1RAB9APOLBHPGD
SCHEMBL24434622 0.89 SMN1; SMN2 (0.43) SMN1; SMN2NPC1RAB9APOLBHPGD
SCHEMBL24434817 0.88 SCD (0.47) SMN1; SMN2NPC1RAB9APOLBHPGD
SCHEMBL24434744 0.88 CSNK2A1 (0.47) SMN1; SMN2NPC1RAB9APOLBHPGD
SCHEMBL24434536 0.88 SCN3A (0.48) SMN1; SMN2NPC1RAB9APOLBHPGD
SCHEMBL24434729 0.87 NPC1 (0.62) SMN1; SMN2NPC1RAB9APOLBHPGD
SCHEMBL24434861 0.87 AOC3 (0.48) SMN1; SMN2NPC1RAB9APOLBHPGD
SCHEMBL24435068 0.86 CNR2 (0.41) SMN1; SMN2NPC1RAB9APOLBHPGD
SCHEMBL26245985 0.85 PDE5A (0.47) SMN1; SMN2NPC1RAB9APOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3930849-B1 THIAZOLE DERIVATIVES AS PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2025-02-19 EP disclosed
US-20220153732-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220153732-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G SMN1; SMN2 4057/4885NPC1 407/4885RAB9A 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.